RECURRENT PRIMARY AMYLOIDOSIS
Clinical trials for RECURRENT PRIMARY AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PRIMARY AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for RECURRENT PRIMARY AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets rare protein disease in early trial
Disease control CompletedThis early-phase trial tested a combination of three drugs—daratumumab, ixazomib, and dexamethasone—in 21 people with AL amyloidosis, a rare disease where abnormal protein builds up in organs. The main goal was to find the safest dose and check for side effects. Researchers also …
Matched conditions: RECURRENT PRIMARY AMYLOIDOSIS
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Experimental antibody shows promise for rare amyloid disease
Disease control CompletedThis phase II trial tested the drug isatuximab in 43 patients with AL amyloidosis that had come back or stopped responding to treatment. Isatuximab is a monoclonal antibody that may help stop abnormal protein buildup. The study measured how well the drug reduced disease markers a…
Matched conditions: RECURRENT PRIMARY AMYLOIDOSIS
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 26, 2026 15:04 UTC